FIG. 3.

Serotype III GBS engages hSiglec-9 through Sias present on the CPS. FITC-GBS (serotype III) were treated with trypsin in order to degrade bacterial surface proteins or with exogenous sialidase to remove all cell surface sialic acid and tested for their ability to bind hSiglec-9-Fc chimeras in comparison to serotype III ΔNeuA. The graphs show mean percent binding ± standard deviation for one representative experiment that was repeated three times with similar results. P values are from two-tailed t tests.